Figure 4.

Anti-miR-25-3p, anti-miR-15a-5p and docetaxel (DXT) have antitumor effects in ovarian cancer mouse models. SKOV3IP1 or resistant SKOV3-TR ovarian tumor-bearing mice treated with anti-miR-25-3p and/or anti-miR-15a-5p (200 μg kg⁻¹ body weight/intravenous) plus DXT (75 μg intraperitoneally) for 5 weeks exhibited lower tumor weights (a), fewer tumor nodules (b), more TUNEL (terminal deoxinucleotidyl transferase-mediated dUTP-fluorescein nick end labeling)-positive cells (c), lower Ki67 index (d) and lower microvessel density (CD31-positive staining) (e) than tumor-bearing mice treated with negative control (NC) anti-miR plus DXT. Quantification of apoptosis (f), proliferation (g) and angiogenesis (h) and in vivo. Data are presented as means±s.d. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001; n=10 mice per group.